Clinical Trials Logo
  1. Home
  2. Bile Duct Neoplasms
  3. NCT03838913

Whole-Exome Sequencing (WES) of Intraductal Neoplasms of the Bile Duct (IPNB) — WESIPNB  

Bile Duct Neoplasms Clinical Trial

Official title:
Classification of Mutation Characteristics by Whole-Exome Sequencing (WES) in Intraductal Neoplasms of the Bile Duct (IPNB) Patients

Clinical Trial Summary

Intraductal papillary neoplasm of the bile duct (IPNB) is a distinct type of biliary tumor characterised with delicate fibrovascular stalks (papillary of villous) covered at biliary epithelium. The typical pathologic feature is dramatical dilation of affected bile ducts due to obstruction by mucin production. IPNB has a better prognosis than bile duct carcinoma, but the current proposed entity contains multiple definitions or categories, thus confused in pathology.

Although mutations of several genes on IPNBs (such as GNAS, KRAS, APC, CTNNB1, and RNF43) identified in previous studies, there is still an unification at gene expression signature.

This research trial will use whole exome sequencing and subsequent bioinformatic analysis in finding causative mutations in deoxyribonucleic acid (DNA) samples from IPNBs patients.

Clinical Trial Description

Using production-scale platform, this study will carry out whole exome sequencing from archival (FFPE) material to Identification and classification of significantly mutated genes, determine the somatic genomic alterations that may be relevant to the development or treatment of cancer, establish classification of IPNBs gene mutation signature. Next, analysis of gene mutation signature and IPNBs clinicopathologic outcomes, including the association between pathologic type, long-term oncological outcomes and gene mutation signature. Last, the determination of involved signal pathways at IPNB patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03838913
Study type Observational
Source Fujian Provincial Hospital
Contact Yaodong Wang, Prof
Phone 18105010560
Email nanfangg@gmail.com
Status Not yet recruiting
Phase
Start date February 15, 2019
Completion date December 31, 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05600803 - Screening Single-operator Cholangioscopy for Neoplastic Bile Duct Lesions
Recruiting NCT05286814 - M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma Phase 2
Recruiting NCT06115655 - A Single-center, Prospective Cohort Study on the Differentiation of Benign and Malignant Bile Duct Stenosis Based on Bile and Peripheral Blood cfDNA Methylation Profiles
Enrolling by invitation NCT03951324 - Volumetric Laser Endomicroscopy's (VLE) Diagnostic Accuracy Validation Study: Impact on Clinical Management Study
Active, not recruiting NCT05374122 - AI Guidance for Biopsy in Suspected Cholangiocarcinoma N/A
Terminated NCT04276090 - Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma N/A
Completed NCT01232101 - Covered or Uncovered Bile Duct Stents N/A
Active, not recruiting NCT00582647 - Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract
Recruiting NCT00915863 - Evaluation of Isolated Roux-en-Y Reconstruction After Pancreaticoduodenectomy N/A
Recruiting NCT05172310 - PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI Phase 1
Recruiting NCT05320328 - RADIO FREQUENCY ABLATION IN UNRESECTABLE MALIGNANT BILIARY OBSTRUCTION
Completed NCT01845337 - Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine Phase 2
Completed NCT04847167 - Mechanistic Loop Resolution Strategy for Short-type Single Balloon Enteroscopy N/A
Completed NCT00634751 - CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma Phase 1/Phase 2